Navigation Links
Celebrex-derived drug targets common childhood bone tumor
Date:6/21/2012

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

Osteosarcoma is an aggressive bone tumor that usually develops during the period of rapid growth that occurs in adolescence. A signaling pathway known as the STAT3 pathway is common in osteosarcoma and is crucial to tumor formation and cancer progression. Blocking STAT3 signaling is considered a potential approach for treating osteosarcoma; however, few drugs are available that can inhibit STAT3 and be clinically relevant.

"One of the main barriers to developing a clinical drug to inhibit STAT3 is finding lead compounds that exhibit desirable drug properties," says Dr. Lin, who is a principal investigator in the Center for Childhood Cancer at The Research Institute at Nationwide Children's Hospital.

Dr. Lin and associate professor at The Ohio State University College of Pharmacy, Chenglong Li, PhD, have found that developing STAT3-selective inhibitors can be accelerated by pairing a novel STAT3 drug discovery method with drug repositioning techniques to create inhibitors with desirable drug properties. Using this method, Dr. Lin's team has developed a STAT3-selective inhibitor, 8A, using the FDA-approved drug, celecoxib (brand name: Celebrex, Pfizer, New York ). Celecoxib is typically prescribed to relieve pain, tenderness, swelling and symptoms of inflammatory conditions like osteoarthritis. 8A is more potent and selective than celecoxib against STAT3 signaling in osteosarcoma cells.

The new funding will allow Dr. Lin's team to develop two additional 8A analogs that would further increase STAT3 binding, while retaining the drug properties of celecoxib. The team will then test all three versions in human and canine osteosarcoma cell lines and in a mouse tumor model. Future research will include collaboration with Cheryl London, DVM, PhD, at The Ohio State University College of Veterinary Medicine to initiate clinical trials of a lead 8A analog in dogs with spontaneous osteosarcoma. Osteosarcoma in dogs is very similar to osteosarcoma in humans. Trials will provide valuable data for human trials as well as help determine the feasibility of using lead 8A analog to treat these tumors in canines.

"This is a unique approach in osteosarcoma targeted therapy," says Dr. Lin. "We feel confident that our findings will advance the field of childhood osteosarcoma treatments."


'/>"/>

Contact: Erin Pope
Erin.Pope@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Gene sequencing project identifies potential drug targets in common childhood brain tumor
2. Identity Theft Expert Advises on Why Elders are Targets for Scams and Financial Abuse
3. A closer look at PARP-1 reveals potential new drug targets
4. SMART heart eases heart ache, targets cardiac patients emotional well-being
5. Mayo Clinic: Common blood pressure drug linked to severe GI problems
6. PTSD Symptoms Common After Heart Attack: Study
7. New delivery method improves efficacy of 2 common Parkinsons disease medications
8. Absentminded Errors Common in Older Adults: Study
9. Colds May Be Even More Common Than People Think
10. Sexting Common Among Teens: Survey
11. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... July 24, 2017 , ... Three experts ... Medicine (AAPM) 59th Annual Meeting & Exhibition, to be held in Denver, CO ... hospital administrators and journalists can visit the AAPM Facebook page to watch three ...
(Date:7/23/2017)... Rosa, CA (PRWEB) , ... July 23, 2017 , ... ... of Medicine in St. Louis, and led by the Minneapolis Veterans Administration Health Care ... early stages of the disease offers very few benefits. , In the cases ...
(Date:7/23/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 23, ... ... the effects of single sport specialization is critical, say researchers presenting their work ... Meeting in Toronto, Canada. , “Our study is the first one to ...
(Date:7/23/2017)... ... 23, 2017 , ... Technology is making it easier for ... tools are helping patients become more actively involved in their care and maintaining ... survey, released today by the American Hospital Association’s (AHA) Health Forum. , According ...
(Date:7/23/2017)... ... 23, 2017 , ... Longtime Brevard County pain management specialist ... practice owned by Physician Partners of America at 109 Silver Palm Ave. , ... certified in pediatrics, emergency medicine and anesthesiology. , A longtime practitioner in the ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... FREMONT, Calif. , July 13, 2017 RK ... (CA) Board of Pharmacy certification for its Fremont, ... chain support solutions in the Tri-Valley and San ... The City of Fremont , with its ... Logistics Group to provide such a powerful resource to the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/10/2017)...  US medical equipment and supply demand is forecast ... Medical Equipment & Supplies: United States , ... increases in demand for medical services – driven in ... supported by gains in disposable personal income – will ... introductions will also drive sales as providers and patients ...
Breaking Medicine Technology: